Pharma & Biotech - Page 5

Novartis has announced positive topline results from its Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib is a highly selective and potent oral Bruton’s tyrosine kinase inhibitor

The pharmaceutical industry faces mounting pressure as blockbuster drug patents expire, opening markets to both generic and biosimilar competitors across the globe. Patent cliffs represent moments when brand-name drug manufacturers lose exclusivity,

Emergent BioSolutions (NYSE: EBS) is ramping up its opioid overdose education efforts across North America in recognition of International Overdose Awareness Day. The company is targeting college campuses across the United States

The FDA is pressing ahead with national licensure standards for wholesale distributors and third-party logistics providers, raising urgent questions across the pharmaceutical supply chain. At the heart of the debate is whether

The White House has announced a second wave of most favoured nation drug pricing agreements, this time targeting nine medium-sized pharmaceutical companies across multiple continents. The latest round includes Alcon, Astellas Pharma,

The Trump administration has added nine pharmaceutical companies to its Most-Favored-Nation pricing program, bringing the total number of participating drugmakers to 26. President Donald J. Trump announced the expansion on August 31,

Lonza, widely regarded as the world’s leading contract development and manufacturing organisation, has named Samanta Cimitan as its new Chief Commercial Officer, Senior Vice President and Member of the Extended Executive Committee.

Cencora’s senior director of manufacturer operations and data services, Ameer Ali, is raising the alarm over the scale of disruption that the pharmaceutical industry faces in transitioning to the 12-digit NDC format.

PharmaEssentia has secured a significant regulatory milestone as the FDA approved a label expansion for its rare blood cancer drug Besremi, known generically as ropeginterferon alfa-2b-njft. The drug, first approved by the

Artis BioSolutions has launched a new Genetic Medicines Center of Excellence in Bilbao, Spain, expanding its integrated development and manufacturing capabilities. The facility strengthens the San Diego-based company’s position as a technology